id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285867-61y4aamj	Kichloo, Asim	Atezolizumab-Induced Bell’s Palsy in a Patient With Small Cell Lung Cancer	2020-10-13		.txt	text/plain	1973	124	43	Neurotoxicity is a rare complication of immune checkpoint inhibitor therapy, and facial palsy as a complication of atezolizumab therapy has only been reported in one additional study. We present the case of a 68-year-old female with a history of small cell carcinoma of the lung presenting with sudden-onset facial palsy and numbness of the distal extremities in the setting of receiving atezolizumab immunotherapy. Clinicians should be aware of this rare adverse effect in order to enact early management including temporary cessation of therapy to prevent morbidity in patients undergoing immunotherapy. 10 Facial palsy secondary to immune checkpoint inhibitor therapy is rare, occurring in only 5 of 364 patients in one retrospective study. Facial palsy is a rare side effect of immune checkpoint inhibitor therapy with atezolizumab. The diagnosis of facial palsy secondary to immune checkpoint inhibitor therapy is one of exclusion, and clinicians should be aware of this as a potential adverse event.	./cache/cord-285867-61y4aamj.txt	./txt/cord-285867-61y4aamj.txt